Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company developing induced pluripotent stem cell (iPSC)-derived, off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. This news page aggregates company press releases, clinical updates, financial disclosures, and corporate announcements so readers can follow how Fate Therapeutics’ iPSC-derived CAR T-cell and NK-cell programs progress over time.
Recent news from Fate Therapeutics has highlighted updated Phase 1 clinical data for FT819, its off-the-shelf CD19-targeted CAR T-cell product candidate for systemic lupus erythematosus (SLE), including reports of sustained reductions in disease activity scores, B-cell depletion with immune remodeling, and a favorable safety profile with less-intensive or no conditioning chemotherapy. The company has also issued news on regulatory authorizations to expand FT819 trials into the United Kingdom and European Union, initiation of dose-expansion cohorts in additional autoimmune diseases, and presentations at major medical meetings such as the American College of Rheumatology (ACR) Convergence and the American Society of Hematology (ASH) Annual Meeting.
In oncology, Fate Therapeutics’ news flow includes updates on FT825 / ONO-8250 for advanced HER2-positive solid tumors and FT836, a MICA/B-targeted CAR T-cell program being evaluated without conditioning chemotherapy, as well as preclinical progress on FT839, a dual CAR T-cell candidate co-targeting CD19 and CD38. Investors can also find quarterly financial results, details of corporate restructuring to streamline operations and extend cash runway, and information on executive appointments and employee inducement equity awards.
By reviewing the FATE news feed, readers can track clinical milestones, regulatory interactions, conference presentations, and corporate developments that shape the company’s iPSC-derived cell therapy pipeline. Bookmark this page for a consolidated view of Fate Therapeutics’ latest publicly released information.
Fate Therapeutics (NASDAQ: FATE) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its FT819 therapy, an off-the-shelf CAR T-cell treatment for moderate to severe systemic lupus erythematosus (SLE).
The RMAT designation was granted based on initial clinical safety and activity data from an ongoing Phase 1 study. The trial evaluates a fludarabine-free conditioning regimen with either bendamustine or cyclophosphamide alone, followed by a single FT819 dose. The company is currently expanding dosing to up to 10 patients at 360 million cells and assessing safety at 900 million cells.
The development is supported by a $7.9 million grant from the California Institute of Regenerative Medicine. Additional Phase 1 clinical data will be presented at medical conferences in 2025. The RMAT designation enables expedited development and review, including potential accelerated approval pathways and priority review.
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced new employee inducement awards. The company granted restricted stock units (RSUs) for 32,200 shares of common stock to two newly-hired non-executive employees on April 1, 2025.
The grants, approved by the Compensation Committee under the Company's Amended and Restated Inducement Equity Plan, will vest over four years, with 25% vesting annually on each grant date anniversary. The awards comply with Nasdaq Listing Rule 5635(c)(4) and are contingent on continuous employment through each vesting date.
VALERIO THERAPEUTICS, a French pharmaceutical company headquartered in Paris, has disclosed information regarding its board members' positions in other companies as of March 19, 2025. The company, which operates with a share capital of €21,610,998.20, is structured as a société anonyme (French public company) with a board of directors. The company's registered office is located at 49 boulevard du Général Martial Valin in Paris's 15th arrondissement.
Fate Therapeutics (NASDAQ: FATE) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company has initiated Phase 1 dose expansion for its FT819 off-the-shelf CAR T-cell product in SLE patients, using a fludarabine-free conditioning regimen.
Key developments include successful treatment of the first patient with FT819 without conditioning chemotherapy, completion of a Type D FDA meeting enabling expansion to additional autoimmune diseases, and advancement of the FT825/ONO-8250 program in solid tumors. The company presented promising clinical data for both FT819 and FT825 programs at major medical conferences.
Financial highlights:
- Cash position: $306.7 million as of December 31, 2024
- Q4 2024 revenue: $1.9 million
- Operating expenses: $63.6 million
- Projected runway through year-end 2026
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced a new employee inducement award. On March 3, 2025, the company granted restricted stock units (RSUs) for 24,000 shares of common stock to one newly-hired non-executive employee.
The grant, approved by the Compensation Committee under the Company's Amended and Restated Inducement Equity Plan, complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, with 25% of shares vesting annually on each grant date anniversary, contingent on continuous employment.
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced its participation in four major upcoming investor conferences in February and March 2025:
• H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Fireside chat on February 25 at 1:30 PM ET
• TD Cowen 45th Annual Health Care Conference - Company presentation in Boston on March 3 at 11:50 AM ET
• Barclays 27th Annual Global Healthcare Conference - Fireside chat in Miami on March 11 at 8:30 AM ET
• Leerink Partners Global Healthcare Conference - Fireside chat in Miami on March 12 at 11:20 AM ET
Live webcasts of the presentations, when available, can be accessed through the Investors section of Fate Therapeutics' website under 'Events & Presentations,' with archived recordings available shortly after each event.
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, announced new employee inducement awards on February 4, 2025. The company granted stock options to one non-executive employee to purchase 35,000 shares at $1.27 per share, and restricted stock units (RSUs) for 20,400 shares to two non-executive employees.
The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months. The RSUs will vest over four years, with 25% vesting annually. These grants were approved by the Compensation Committee under the company's Amended and Restated Inducement Equity Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement awards. On January 2, 2025, the company granted stock options to two new non-executive employees to purchase 72,000 shares at $1.79 per share, which was the closing price on the grant date.
Additionally, one newly-hired non-executive employee received restricted stock units (RSUs) representing 3,200 shares. The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months. The RSUs will vest in four equal annual installments of 25% each, subject to continuous employment.
Fate Therapeutics (NASDAQ: FATE) presented new Phase 1 clinical data for FT819, its off-the-shelf CAR T-cell therapy for systemic lupus erythematosus (SLE). Three patients with active lupus nephritis received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells.
The treatment showed promising results with no dose-limiting toxicities, no cytokine release syndrome, and no immune effector-cell associated neurotoxicity. All patients demonstrated rapid B-cell depletion, with the first patient achieving DORIS clinical remission at 6 months and remaining free of immunosuppressive therapy.
Based on these positive results, the company plans to initiate dose expansion at the first dose level to include up to 10 patients and escalate dosing to 720 million cells. Additionally, the first patient has been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy.
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has granted 18,600 restricted stock units (RSUs) to a new non-executive employee. The grant, approved by the company's Compensation Committee, was made under the Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually on each grant date anniversary, contingent on continuous employment.
FAQ
What is the current stock price of Fate Therapeutic (FATE)?
What is the market cap of Fate Therapeutic (FATE)?
